Results 151 to 160 of about 44,548 (260)

Unexplained Elevated Vitamin B12: Consider Macro‐B12

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 646-651, June 2026.
ABSTRACT Introduction Elevated vitamin B12 concentration can be caused by supplementation, liver disease, kidney disease, or myeloid malignancies. Persistent, unexplained elevations of vitamin B12 can raise concern among patients and may lead to invasive diagnostic procedures, including bone marrow biopsy.
Evelien G. E. Hurkmans, Ruben Deneer, Marten R. Nijziel, Volkher Scharnhorst   +3 more
wiley   +1 more source

Evaluation of the association between the JAK2 46/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population

Clinics, 2013
OBJECTIVE: The JAK2 46/1 haplotype has recently been described as a major contributing factor to the development of myeloproliferative neoplasm, whether positive or negative forthe JAK2 V617F mutation.
Sarah Pagliarini-e-Silva, Bruna Cunha Santos, Elizangela Mendes de Figueiredo Pereira, Mari Ellen Ferreira, Elaine Cristina Baraldi, Ana Maria Sell, Jeane Eliete Laguila Visentainer   +6 more
doaj  

Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment

Journal of Neuroendocrinology, Volume 38, Issue 6, June 2026.
Abstract Neuroendocrine tumours (NETs) are well‐differentiated epithelial neuroendocrine neoplasms that frequently develop in the small intestine, pancreas, and lungs. NETs originate from neuroendocrine cells specialized in hormone secretion implicated in a number of physiological processes.
Victoria Jacquot, Benjamin Chevalier, Thomas Walter, Benjamin Gibert, Maria Ouzounova   +4 more
wiley   +1 more source

Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients

Haematologica, 2017
Elizabeth Margolskee, Spencer Krichevsky, Attilio Orazi, Richard T. Silver   +3 more
doaj   +1 more source

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

Cancer, Volume 132, Issue 10, 15 May 2026.
Abstract Background ASXL1 mutations (ASXL1MUT) are common in acute myeloid leukemia (AML) and have historically conferred an adverse prognosis with intensive chemotherapy. Given the increasing use of venetoclax (VEN)‐based lower intensity therapy (LIT), the European LeukemiaNet introduced a four‐gene genetic risk classifier in 2024 that categorizes ...
Jennifer Marvin‐Peek, Courtney D. DiNardo, Sanam Loghavi, Farhad Ravandi, Gautam Borthakur, Naval G. Daver, Tapan M. Kadia, Elias Jabbour, Andrew Dunbar, Guilin Tang, Nicholas J. Short, Fadi G. Haddad, Hussein A. Abbas, Eitan Kugler, Abhishek Maiti, Ghayas C. Issa, Koichi Takahashi, Kapil Bhalla, Naveen Pemmaraju, Yesid Alvarado, Elizabeth J. Shpall, Uday Popat, Jeremy Ramdial, Richard E. Champlin, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Jayastu Senapati   +26 more
wiley   +1 more source

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study

Cancer, Volume 132, Issue 10, 15 May 2026.
Momelotinib demonstrated robust real‐world activity after ruxolitinib failure, with clinically meaningful improvements in spleen (≥50% spleen length reduction, 30.0%), symptoms (≥50% total symptoms score reduction, 39.2%), and anemia (major response, 35.7%) at 6 months.
Francesca Palandri, Monia Marchetti, Elena M. Elli, Alessandro Isidori, Ilaria Gianesello, Chiara Sartor, Novella Pugliese, Maria Di Perna, Erika Morsia, Susanna Gallo, Federico Itri, Vittorio Montefusco, Elena Crisà, Annalisa Biagi, Eloise Beggiato, Olga Mulas, Giulia Benevolo, Elisabetta Abruzzese, Marco Santoro, Alessandra Iurlo, Elisabetta Calistri, Marco Rossi, Bruno Martino, Mario Tiribelli, Carmen Fava, Arbana Dizdari, Monica Crugnola, Andrea Duminuco, Amedeo Votto, Selene Guerzoni, Giovanni Caocci, Fabrizio Pane, Francesco Lanza, Filippo Branzanti, Alessandra Dedola, Flavia Salvatore, Florian H. Heidel, Massimo Breccia, Giuseppe A. Palumbo, Andrew T. Kuykendall, Alessandro Lucchesi, Sara Galimberti   +41 more
wiley   +1 more source

An agenda for future research projects in polycythemia vera and essential thrombocythemia

Haematologica, 2020
Tiziano Barbui, Alessandro Maria Vannucchi, Paola Guglielmelli, Valerio De Stefano, Alessandro Rambaldi   +4 more
doaj   +1 more source

Are Myeloproliferative Neoplasms-Unclassifiable Really Unclassifiable? [PDF]

EJHaem
Barosi G, Rosti V, Gale RP.
europepmc   +1 more source

Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): A prospective observational study of patients with polycythemia vera in the United States [PDF]

, 2018
Boccia, Ralph V, Colucci, Philomena, Grunwald, Michael R, Mesa, Ruben, Oh, Stephen T, Paranagama, Dilan, Parasuraman, Shreekant, Stein, Brady L   +7 more
core   +2 more sources

Are thrombosis, progression, and survival in ET predictable?

Blood Cancer Journal
Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Ahamed Lebbe, Imane Bouhali, Mohammed Khalid, Richard T. Silver, Joseph M. Scandura   +7 more
doaj   +1 more source